About this trial
The purpose of this trial is to compare the effects of using standard doses of chemotherapy with the effects of using high-doses of chemotherapy for treatment of relapsed testicular germ cell tumours.
Both of these types of chemotherapy have been shown to shrink germ cell tumour when given as the second chemotherapy treatment, but it is not known whether one type is better than the other.
This is a radmonised Phase III trial that will allow researchers to learn whether the high-dose chemotherapy is better, the same, or worse than the standard dose chemotherapy.
Patients who have a diagnosis of a testicular germ cell tumour that has got worse or come back following your first chemotherapy treatment
Where’s this trial being run?St James’s Hospital
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.Print this page
For more detailed informationClick Here
A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First Salvage Treatment in Relapsed or Refractory Germ Cell Tumors
|Principal Investigator:||Dr Dearbhaile O'Donnell (St James' Hospital)|
EORTC-European Organisation for Research and Treatment of Cancer. The trial sis being conducted by a clinical research group called Alliance for Clinical Trials in Oncology in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC), ICR, Unicancer, KKS, Cancer Trials Ireland, Orchid and Movember.
Global: March 2015
Ireland: January 2017
|Global Recruitment Target:||420|
|Ireland Recruitment Target:||7 per year|